Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02179996
Other study ID # 2013-A01377-28
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received July 1, 2014
Last updated July 27, 2015
Start date January 2014
Est. completion date September 2015

Study information

Verified date July 2015
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority France: CPP
Study type Interventional

Clinical Trial Summary

Preterm neonates are fragile to infections. Their immune system is immature, yet in France, primary vaccines are injected at two months of age, as in term infants.

Recommendations for vaccinations in infants have changed in France in 2013, suppressing the second injection at three months after birth. Preterm and full-term born infants are now vaccinated at two and four months of age, but no data regarding efficacy in very preterm infants have been registered.

The investigators hypothesize that two vaccine injections (at two and four months) would be less efficient than three injections (two, three and four months) in very preterm-born infants.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 160
Est. completion date September 2015
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender Both
Age group N/A to 6 Months
Eligibility Inclusion Criteria:

- infants born < 33 weeks gestation in Nancy and Thionville Maternity Wards

- signed parental consent

Exclusion Criteria:

- immunodeficiency

- vaccine contra-indication

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Three vaccine injections DTP-pertussis-Hib
DTP-pertussis-Hib injections at two, three, four months after birth
Two vaccine injections DTP-pertussis-Hib
DTP-pertussis-Hib injections are administered at two and four months after birth

Locations

Country Name City State
France Centre Hospitalier Regional et Universitaire, Maternite Regionale Nancy
France Centre Hospitalier de Thionville Thionville

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hib antibody dosage in blood sample 5 months after birth No
Secondary Pertussis antibody dosage in blood sample 5 months after birth No